Trade AVTX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Avalo Therapeutics, Inc. (AVTX) is trading at US$19.59, down 2.29% today as of Aug 28, 16:00 EDT. The company has a market capitalisation of US$1.06B. Over the past 52 weeks, AVTX has traded between US$8.65 and US$24.27. On Syfe you can trade AVTX with $0 commission and add it to your watchlist.
| Previous close | US$20.05 |
|---|---|
| Market cap | US$1.06B |
| 52-week range | US$8.65 – US$24.27 |
| Volume | 738.28K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
Year: 2015
Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares
Jul 17, 8:22 PM · MT Newswires
Sector Update: Healthcare Stocks Mixed Premarket Friday
Jun 26, 1:16 PM · MT Newswires
Avalo Therapeutics to Join Russell 2000, Russell 3000 Indexes
Jun 26, 11:39 AM · MT Newswires
Avalo Therapeutics Plans IND Application for AVTX-010 in H1 2027
Jun 16, 1:19 PM · MT Newswires
Avalo Therapeutics, Inc. (AVTX) stock is trading at US$19.59, -2.29% from the previous close of US$20.05.
The market cap for Avalo Therapeutics, Inc. (AVTX) stock is approximately US$1.06B.
The 52-week high for Avalo Therapeutics, Inc. (AVTX) stock is US$24.27.
The 52-week low for Avalo Therapeutics, Inc. (AVTX) stock is US$8.65.
Avalo Therapeutics, Inc. (AVTX) does not currently pay a dividend.
Stay on top of AVTX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
